RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Royalty Pharma Stock

Royalty Pharma EBIT 2024

Royalty Pharma EBIT

2 B USD

Ticker

RPRX

ISIN

GB00BMVP7Y09

WKN

A2P62D

In 2024, Royalty Pharma's EBIT was 2 B USD, a 34.03% increase from the 1.49 B USD EBIT recorded in the previous year.

The Royalty Pharma EBIT history

YEAREBIT (undefined USD)
2029e2.47
2028e2.41
2027e2.31
2026e2.41
2025e2.3
2024e2
20231.49
20220.92
20211.43
20201.66
20192.62
20181.36
20170.94

Royalty Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Royalty Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Royalty Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Royalty Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Royalty Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Royalty Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Royalty Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Royalty Pharma’s growth potential.

Royalty Pharma Revenue, EBIT and net profit per share

DateRoyalty Pharma RevenueRoyalty Pharma EBITRoyalty Pharma Net Income
2029e2.99 B undefined2.47 B undefined4.3 B undefined
2028e2.88 B undefined2.41 B undefined4.16 B undefined
2027e2.75 B undefined2.31 B undefined3.64 B undefined
2026e3.25 B undefined2.41 B undefined2.9 B undefined
2025e2.94 B undefined2.3 B undefined2.63 B undefined
2024e2.64 B undefined2 B undefined2.34 B undefined
20232.35 B undefined1.49 B undefined1.13 B undefined
20222.24 B undefined922.9 M undefined42.8 M undefined
20212.29 B undefined1.43 B undefined619.7 M undefined
20202.12 B undefined1.66 B undefined495.2 M undefined
20191.81 B undefined2.62 B undefined2.35 B undefined
20181.79 B undefined1.36 B undefined1.38 B undefined
20171.6 B undefined939.7 M undefined1.21 B undefined

Royalty Pharma stock margins

The Royalty Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Royalty Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Royalty Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Royalty Pharma's sales revenue. A higher gross margin percentage indicates that the Royalty Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Royalty Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Royalty Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Royalty Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Royalty Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Royalty Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Royalty Pharma Margin History

Royalty Pharma Gross marginRoyalty Pharma Profit marginRoyalty Pharma EBIT marginRoyalty Pharma Profit margin
2029e0 %82.77 %143.76 %
2028e0 %83.48 %144.3 %
2027e0 %83.82 %132.38 %
2026e0 %74.19 %89.21 %
2025e0 %78.27 %89.57 %
2024e0 %75.7 %88.72 %
20230 %63.37 %48.2 %
20220 %41.25 %1.91 %
20210 %62.49 %27.07 %
20200 %78.24 %23.33 %
20190 %144.58 %129.44 %
20180 %76.02 %76.76 %
20170 %58.81 %75.72 %

Royalty Pharma Aktienanalyse

What does Royalty Pharma do?

Royalty Pharma PLC is a US-based company specializing in investments in biopharmaceutical companies and their products. The company was founded in 1996 by Pablo Legorreta and is headquartered in New York City. It has subsidiaries in Bermuda, Ireland, Luxembourg, and Switzerland. The business model of Royalty Pharma involves providing financial resources to manufacturers of biopharmaceuticals in exchange for a share in the licenses and sales of their products. This allows Royalty Pharma to participate in the development and commercial exploitation of medications without bearing the risk of developing active substances or obtaining approvals. In recent years, Royalty Pharma has invested in a variety of companies to benefit from their commercial success. Examples of companies they work with include Biomarin Pharmaceuticals, Vertex, Teva Pharmaceutical Industries, and General Electric. Royalty Pharma now has a portfolio of over 45 investments in products from companies such as AbbVie, Gilead, Roche, and Amgen. The range of products includes cancer therapies and vaccines, used for both rare diseases and broader applications. One of the most well-known products in Royalty Pharma's portfolio is the cancer drug Kadcyla from Roche. This medication is used in the treatment of breast cancer and has been successful in slowing tumor growth. Another example is the commercial success of the hepatitis C medication Harvoni from Gilead, which improves the quality of life for affected patients and saves lives. Royalty Pharma also has a financing division that focuses on the purchase of existing or future license fees. This division offers credit agreements for biopharmaceutical companies and serves as a good financing alternative for small and medium-sized enterprises. Overall, Royalty Pharma has a successful track record in investing in the biopharmaceutical industry. The model allows the company to benefit from innovative products and their commercial exploitation without taking on the risk of drug development. This allows the company to continue offering attractive returns to its investors. Royalty Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Royalty Pharma's EBIT

Royalty Pharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Royalty Pharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Royalty Pharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Royalty Pharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Royalty Pharma stock

How much did Royalty Pharma achieve in EBIT for the current year?

In the current year, Royalty Pharma has achieved an EBIT of 2 B USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Royalty Pharma.

How has the EBIT of Royalty Pharma developed in recent years?

The EBIT of Royalty Pharma has increased by 34.035% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Royalty Pharma?

The EBIT of Royalty Pharma is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Royalty Pharma pay?

Over the past 12 months, Royalty Pharma paid a dividend of 0.8 USD . This corresponds to a dividend yield of about 3.18 %. For the coming 12 months, Royalty Pharma is expected to pay a dividend of 0.78 USD.

What is the dividend yield of Royalty Pharma?

The current dividend yield of Royalty Pharma is 3.18 %.

When does Royalty Pharma pay dividends?

Royalty Pharma pays a quarterly dividend. This is distributed in the months of March, June, September, December.

How secure is the dividend of Royalty Pharma?

Royalty Pharma paid dividends every year for the past 10 years.

What is the dividend of Royalty Pharma?

For the upcoming 12 months, dividends amounting to 0.78 USD are expected. This corresponds to a dividend yield of 3.1 %.

In which sector is Royalty Pharma located?

Royalty Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Royalty Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Royalty Pharma from 12/10/2024 amounting to 0.21 USD, you needed to have the stock in your portfolio before the ex-date on 11/15/2024.

When did Royalty Pharma pay the last dividend?

The last dividend was paid out on 12/10/2024.

What was the dividend of Royalty Pharma in the year 2023?

In the year 2023, Royalty Pharma distributed 0.76 USD as dividends.

In which currency does Royalty Pharma pay out the dividend?

The dividends of Royalty Pharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Royalty Pharma

Our stock analysis for Royalty Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Royalty Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.